Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genmab
A2 Biotherapeutics Inc.
Zhejiang University
National Institutes of Health Clinical Center (CC)
Azienda Ospedaliero-Universitaria di Parma
Verismo Therapeutics
Lumicell, Inc.
Perspective Therapeutics
Seagen Inc.
Novartis
NeoTX Therapeutics Ltd.
National Institutes of Health Clinical Center (CC)
Actym Therapeutics, Inc.
TCR2 Therapeutics
TCR2 Therapeutics
Incyte Corporation
Numab Therapeutics AG
Medicenna Therapeutics, Inc.
Ascentage Pharma Group Inc.
University of Pennsylvania
Mayo Clinic
Sotio Biotech Inc.
Deciphera Pharmaceuticals, LLC
Aminex Therapeutics, Inc.
Aromics Therapeutics
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
UTC Therapeutics Inc.
Memorial Sloan Kettering Cancer Center
NGM Biopharmaceuticals, Inc
Centre Hospitalier Universitaire Vaudois
Multitude Therapeutics Inc.
Candel Therapeutics, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
Incyte Corporation
Augusta University
AbbVie
AbbVie
MacroGenics
Incyte Corporation
Incyte Corporation
Incyte Corporation
Shenzhen BinDeBio Ltd.
National Institutes of Health Clinical Center (CC)
Novartis
Kantonsspital Winterthur KSW
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)